You are here

Article info

Article menu

Download PDFPDF

Poster Presentation
Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab

Authors

Citation

Forero A, Hamadani M, Kipps T, et al
Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab
Journal for ImmunoTherapy of Cancer 2013;1:P43. doi: 10.1186/2051-1426-1-S1-P43

Publication history

  • First published November 7, 2013.
Online issue publication 
March 11, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). 2013 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.